Bellerophon Therapeutics (BLPH)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.00%)
Updated Sep 18, 2024 02:45 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BLPH 0.04 0.00(0.00%)
Will BLPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BLPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLPH
Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
BLPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
Bellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should Know